Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach
Soligenix is entering a pivotal period marked by several anticipated clinical readouts and milestones expected throughout 2026. At the heart of the Zacks analysis is HyBryte(TM), which Soligenix is evaluating in the Phase 3 FLASH2 study for the treatment of CTCL. Beyond HyBryte, the report also points to progress involving SGX945, or dusquetide, for Behçet’s disease. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing therapies for rare diseases and unmet medical needs, is featured in a detailed research report issued by Zacks Small-Cap Research. The March 12 report provides a comprehensive look at the company’s pipeline, financial positioning…